Ali Naderi1, Luke Hughes-Davies. 1. Diamantina Institute for Cancer, Immunology and Metabolic Medicine, Cancer Biology Program, University of Queensland, Princess Alexandra Hospital, Brisbane, QLD, 4102, Australia. a.naderi@uq.edu.au
Abstract
INTRODUCTION: Nuclear factor-kappaB pathway (NF-kappaB) is activated in many breast cancers. NF-small kappaB has interactions with other pathways such as the nerve growth factor (NGF) pathway, which is involved in the survival and proliferation of breast cancer cells. NGF treatment of breast cancer cells activates NF-kappaB resulting in the inhibition of ceramide-induced apoptosis. NGF effects on apoptosis and cell proliferation are mediated through p75NTR and p140TrkA receptors, respectively. In this study we investigate the NGF/NF-kappaB pathway as a therapeutic target in breast cancer. RESULTS: We demonstrate that p75NTR inhibitor Pep5, p140TrkA inhibitor K-252a, and NF-kappaB inhibitor BAY11-7085 have pro-apoptotic and anti-proliferation activities in breast cancer cells. We also show a synergy in combining the NGF receptor inhibitors with the conventional breast cancer treatments tamoxifen and taxol. CONCLUSION: These data suggest that NGF/NF-kappaB pathway is a potential therapeutic target in breast cancer.
INTRODUCTION: Nuclear factor-kappaB pathway (NF-kappaB) is activated in many breast cancers. NF-small kappaB has interactions with other pathways such as the nerve growth factor (NGF) pathway, which is involved in the survival and proliferation of breast cancer cells. NGF treatment of breast cancer cells activates NF-kappaB resulting in the inhibition of ceramide-induced apoptosis. NGF effects on apoptosis and cell proliferation are mediated through p75NTR and p140TrkA receptors, respectively. In this study we investigate the NGF/NF-kappaB pathway as a therapeutic target in breast cancer. RESULTS: We demonstrate that p75NTR inhibitor Pep5, p140TrkA inhibitor K-252a, and NF-kappaB inhibitor BAY11-7085 have pro-apoptotic and anti-proliferation activities in breast cancer cells. We also show a synergy in combining the NGF receptor inhibitors with the conventional breast cancer treatments tamoxifen and taxol. CONCLUSION: These data suggest that NGF/NF-kappaB pathway is a potential therapeutic target in breast cancer.
Authors: S Descamps; R A Toillon; E Adriaenssens; V Pawlowski; S M Cool; V Nurcombe; X Le Bourhis; B Boilly; J P Peyrat; H Hondermarck Journal: J Biol Chem Date: 2001-02-28 Impact factor: 5.157
Authors: Laurent Dollé; Eric Adriaenssens; Ikram El Yazidi-Belkoura; Xuefen Le Bourhis; Victor Nurcombe; Hubert Hondermarck Journal: Curr Cancer Drug Targets Date: 2004-09 Impact factor: 3.428
Authors: M A Christine Pratt; Tanya E Bishop; Dawn White; Gordon Yasvinski; Michel Ménard; Min Ying Niu; Robert Clarke Journal: Mol Cell Biol Date: 2003-10 Impact factor: 4.272
Authors: Debajit K Biswas; Qian Shi; Shanon Baily; Ian Strickland; Sankar Ghosh; Arthur B Pardee; J Dirk Iglehart Journal: Proc Natl Acad Sci U S A Date: 2004-06-25 Impact factor: 11.205
Authors: L A deGraffenried; B Chandrasekar; W E Friedrichs; E Donzis; J Silva; M Hidalgo; J W Freeman; G R Weiss Journal: Ann Oncol Date: 2004-06 Impact factor: 32.976
Authors: Eric Adriaenssens; Elsa Vanhecke; Pasquine Saule; Alexandra Mougel; Adeline Page; Rodrigue Romon; Victor Nurcombe; Xuefen Le Bourhis; Hubert Hondermarck Journal: Cancer Res Date: 2008-01-15 Impact factor: 12.701
Authors: Ali Naderi; Andrew E Teschendorff; Juergen Beigel; Massimiliano Cariati; Ian O Ellis; James D Brenton; Carlos Caldas Journal: Cancer Res Date: 2007-07-15 Impact factor: 12.701
Authors: Sang Jae Noh; Jun Sang Bae; Urangoo Jamiyandorj; Ho Sung Park; Keun Sang Kwon; Sung Hoo Jung; Hyun Jo Youn; Ho Lee; Byung-Hyun Park; Myoung Ja Chung; Woo Sung Moon; Myoung Jae Kang; Kyu Yun Jang Journal: BMC Cancer Date: 2013-11-01 Impact factor: 4.430